KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study

In recent years, the outcome of mantle cell lymphoma (MCL) has improved, especially in younger patients, receiving cytarabine-containing chemoimmunotherapy and autologous stem cell transplantation. Nevertheless, a proportion of MCL patients still experience early failure. To identify biomarkers anti...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferrero, Simone, Rossi, Davide, Rinaldi, Andrea, Bruscaggin, Alessio, Spina, Valeria, Eskelund, Christian W., Evangelista, Andrea, Moia, Riccardo, Kwee, Ivo, Dahl, Christina, Di Rocco, Alice, Stefoni, Vittorio, Diop, Fary, Favini, Chiara, Ghione, Paola, Mahmoud, Abdurraouf Mokhtar, Schipani, Mattia, Kolstad, Arne, Barbero, Daniela, Novero, Domenico, Paulli, Marco, Zamò, Alberto, Jerkeman, Mats, da Silva, Maria Gomes, Santoro, Armando, Molinari, Annalia, Ferreri, Andres, Grønbæk, Kirsten, Piccin, Andrea, Cortelazzo, Sergio, Bertoni, Francesco, Ladetto, Marco, Gaidano, Gianluca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7271566/
https://www.ncbi.nlm.nih.gov/pubmed/31537689
http://dx.doi.org/10.3324/haematol.2018.214056

Ejemplares similares

Ejemplares similares